000K utf8 1100 $c2023 1500 eng 2050 urn:nbn:de:gbv:8:3-2025-00032-2 2051 10.1024/1662-9647/a000311 3000 Pauli, Philipp 3010 Bartsch, Thorsten 3010 Berg, Daniela Dagmar Denise 3010 Goetz, Katja 3010 Hertrampf, Katrin 3010 Philippen, Sarah 3010 Rogge, Annette 4000 Attitudes and Viewpoints Toward Prevention Trials in Alzheimer’s Disease$hHogrefe Publishing Group [Pauli, Philipp] 4030 $nHogrefe Publishing Group 4209 Alzheimer’s disease (AD) prevention studies use biomarkers to determine risk in asymptomatic study participants. This involves multifaceted implications. Determinants regarding participation in these trials are therefore of particular relevance. We used semistructured individual interviews to interview uninvolved persons (n = 10), relatives of Alzheimer’s patients (n = 10), and patients with mild cognitive impairment (n = 5) and analyzed the interviews using qualitative content analysis according to Mayring. We discovered various factors to be positive motivations for participation; the most significant inhibiting factor was concern about negative psychological effects. These motivations and concerns should be specifically addressed in the study design of AD prevention trials. The fears and concerns expressed highlight the importance of a good methodological and ethical framework to increase participant acceptance. 4950 https://doi.org/10.1024/1662-9647/a000311$xR$3Volltext$534 4950 https://nbn-resolving.org/urn:nbn:de:gbv:8:3-2025-00032-2$xR$3Volltext$534 4961 https://macau.uni-kiel.de/receive/macau_mods_00005553 5051 610 5550 Alzheimer’s disease 5550 barriers 5550 prevention studies 5550 qualitative study 5550 risk disclosure